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Abstract: KRAS oncogenic mutations are widespread in lung cancer and, because direct targeting of
KRAS has proven to be challenging, KRAS-driven cancers lack effective therapies. One alternative
strategy for developing KRAS targeted therapies is to identify downstream targets involved
in promoting important malignant features, such as the acquisition of a cancer stem-like and
metastatic phenotype. Based on previous studies showing that KRAS activates nuclear factor
kappa-B (NF-κB) through inhibitor of nuclear factor kappa-B kinase β (IKKβ) to promote lung
tumourigenesis, we hypothesized that inhibition of IKKβ would reduce stemness, migration
and invasion of KRAS-mutant human lung cancer cells. We show that KRAS-driven lung
tumoursphere-derived cells exhibit stemness features and increased IKKβ kinase activity. IKKβ
targeting by different approaches reduces the expression of stemness-associated genes, tumoursphere
formation, and self-renewal, and preferentially impairs the proliferation of KRAS-driven lung
tumoursphere-derived cells. Moreover, we show that IKKβ targeting reduces tumour cell migration
and invasion, potentially by regulating both expression and activity of matrix metalloproteinase 2
(MMP2). In conclusion, our results indicate that IKKβ is an important mediator of KRAS-induced
stemness and invasive features in lung cancer, and, therefore, might constitute a promising strategy to
lower recurrence rates, reduce metastatic dissemination, and improve survival of lung cancer patients
with KRAS-driven disease.
Keywords: KRAS; lung cancer; IKKβ kinase; stemness; cancer stem cells; NF-κB signalling;
migration; invasion
1. Introduction
Lung cancer is the main cause of cancer-related deaths in the world, and despite the increasing
advances in the development of new, targeted therapies, the 5-year survival rates remain lower than 20%.
The most common genetic alterations found in lung cancer patients include activating-point mutations
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in KRAS, which are present in a third of lung adenocarcinoma patients, and are causally correlated
with poor prognosis [1]. Although there has been promising recent progress in the development of
inhibitors capable to selectively target KRASG12C mutants [2–4], direct inhibition of KRAS has proven
to be remarkably challenging to date [5]. On the other hand, targeting traditional downstream effectors
of KRAS has only reached limited efficacy due to poor therapeutic windows coupled with paradoxical
pathway activation by signalling loops [5]. In order to overcome these challenges, identification and
characterization of new druggable targets in the KRAS-induced signalling pathways that promote
important malignant features is urgently warranted for the development of novel and more effective
therapeutic strategies for lung cancer, as well as other RAS-driven malignancies.
One very important malignant feature of many tumours that has important therapeutic implications
is the existence of malignant cells with stemness properties. These stem-like tumour-initiating cells
(TICs) are able to self-renew and sustain tumour growth and are considered to be one of the main
explanations for tumour resistance, recurrence, and metastasis [6]. Moreover, purification and/or
enrichment of these phenotypically distinct cancer cells from various tumours, including those of
the lung [7], results in a subpopulation of tumour cells with an exceptional tumourigenic capacity
when injected into immunocompromised mice. These cells also display enhanced resistance to
chemotherapeutic drugs, and increased invasive and metastatic capacity [8]. In this regard, oncogenic
KRAS not only drives cancer cell proliferation, but it has been implicated in metastasis formation [9–11]
and in driving the cancer stem-like phenotype [12–16].
One important mechanism driving lung tumourigenesis is the KRAS-mediated activation of the
nuclear factor kappa-B (NF-κB) transcription factor. NF-κB has been shown to promote KRAS-induced
lung tumour growth, proliferation and survival [17,18]. Interestingly, NF-κB has also been implicated
in promoting metastasis in different tumour models [19] and has been extensively implicated in
regulating stemness behaviour of TICs in various tumours [20].
A potential druggable target in the KRAS-induced NF-κB activation pathway is the inhibitor
of nuclear factor kappa-B kinase β (IKKβ). IKKβ is a catalytic subunit of the inhibitor of nuclear
factor kappa-B kinase (IKK) complex, which also includes a second catalytic subunit (IKKα) and a
regulatory subunit (IKKγ). The IKK complex mediates canonical NF-κB activation by phosphorylating
and thereby promoting the proteasome-mediated degradation of the inhibitory protein inhibitor of
nuclear factor kappa-B alpha (IκBα), which sequesters NF-κB in the cytoplasm [19]. Not surprisingly,
NF-κB activation by oncogenic KRAS in the lung involves the canonical pathway [21] and requires
IKKβ [22].
Based on this evidence we hypothesized that IKKβ would promote KRAS-driven lung cancer
stemness and invasion. In support of this hypothesis, genetic or systemic IKKβ inhibition not only
reduces KRAS-induced lung tumour growth by reducing cell proliferation [22,23], but also reduces
KRAS-induced angiogenesis [24], a cancer hallmark that is associated with poor prognosis and
contributes to the process of metastasis [25].
Here, using an established tumoursphere formation assay [15,26] to enrich for lung TICs, we show
that IKKβ is critical to sustain stemness-associated features in KRAS-driven lung cancer cells. Using
pharmacological and genetic approaches, we demonstrate that IKKβ contributes to the expression of
stemness-associated genes, tumoursphere formation and self-renewal. Remarkably, targeting of IKKβ
activity preferentially reduces the proliferation of TICs. Furthermore, IKKβ targeting also decreases
tumour cell migration, invasion and expression of metastasis-associated genes. Finally, our data
suggest that IKKβ kinase inhibition therapy may clinically benefit KRAS-driven lung cancer patients by
depleting the pool of stem-like TICs, thereby decreasing the risk of tumour recurrence and metastasis.
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2. Results
2.1. KRAS-Mutant Lung Tumoursphere-Derived Cells Exhibit Stemness Features and Increased IKKβ
Kinase Activity
Because IKKβ targeting in KRAS-induced lung cancer reduces tumour histological grade,
angiogenesis and is required for activation of NF-κB [17,22,24], which, in turn, has been shown
to be critical for TIC activity in different contexts [20], we hypothesised that IKKβ would be activated
in KRAS-induced lung TICs. In order to test this hypothesis, we used a well-established tumoursphere
culture system to enrich for TICs [15,26]. As expected, when compared to adherent cultures,
KRAS-mutant A549 or H358 tumoursphere-derived cells were more clonogenic (Figure 1A) and
expressed significantly elevated levels of stemness-related genes SRY (sex determining region Y)-box
2 (SOX2), NANOG, octamer-binding transcription factor 4 (OCT4), and C-X-C chemokine receptor
type 4 (CXCR-4) (Figure 1B). A549 tumourspheres also had increased expression of B cell-specific
Moloney murine leukaemia virus integration site 1 (BMI1) and the stem cell surface marker cluster
of differentiation (CD) 24. Remarkably, when compared to adherent cells, both A549 and H358
tumourspheres displayed a 3.2-fold and a 2.0-fold increase in phosphorylation of the IKKβ substrate
IκBα respectively (Figure 1C and Figure S1). Total IκBα, which is an NF-κB-activated gene, was also
increased by 2.32-fold and 1.62-fold, respectively, indicating increased activity of the IKK/NF-κB
pathway in KRAS-positive lung tumourspheres enriched for TIC activity.
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Figure 1. KRAS-mutant tumoursphere-derived cells exhibit stemness features and increased IKKβ
kinase activity. (A) Clonogenic assays of adherent (AD) and tumoursphere-derived (TS) A549 and
H358 cells. Cells were plated and colonies formed were stained with crystal violet and colony area was
analysed using Image J software. Images shown are representative of three independent experiments.
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(B) Relative expression of SOX2, OCT4, NANOG, CXCR4, BMI1, and CD24 was analysed by real-time
quantitative PCR in adherent (AD) and tumoursphere-derived (TS) A549 and H358 cells using β-ACTIN
as endogenous control. (C) Western blotting of adherent (AD) and tumoursphere-derived (TS) A549
and H358 cells. Antibodies used are indicated. Protein bands were quantitated and normalized to
the reference sample using ImageJ software. Nitrocellulose membrane was cut before probing with
the respective primary antibody and full membrane blots are presented in Figure S1. Images shown
are representative of three independent experiments. In all cases, bar graphs represent average ±1
SD of three independent experiments (n = 3). Statistical significance was determined by Student’s
t-test (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Groups being compared are indicated by
horizontal bars.
2.2. IKKβ Targeting in KRAS-Positive Lung Cancer Cells Reduces the Expression of Stemness-Associated Genes
Next, we targeted IKKβ with Compound A (CmpdA), a highly selective IKKβ inhibitor [27].
As expected, CmpdA treatment reduced IκBα phosphorylation consistent with inhibition of IKKβ
activity (Figure 2A and Figure S2). Interestingly, looking at expression of a panel of stemness-related
genes, we found that IKKβ inhibition in KRAS-positive A549 cells significantly reduced expression of
stem cell transcription factors SOX2, NANOG, OCT4, and BMI1, as well as the TIC surface marker
CXCR-4 (Figure 2B, left panel). With the exception of BMI1, identical results were obtained by
CmpdA-mediated IKKβ targeting in KRAS-mutant H358 cells (Figure 2B, right panel).
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Figure 2. IKKβ targeting reduces the expression of stemness-associated genes in KRAS-mutant lung
cancer cells. (A) Western blotting of A549 and H358 cells treated with 0.1% DMSO or 5 µM Compound
A (CmpdA) for 30 min. Antibodies were used as indicated. Nitrocellulose membrane was cut before
probing with the respective primary antibody and full membrane blots are presented in Figure S2.
Representative western blots are shown. Protein bands were quantitated and normalized to the
reference samples (0.1% DMSO-treated samples) using Image J software. (B) A549 and H358 cells were
tre ted with 0.1% DMSO or the indicated concentrations of CmpdA for 48 h and expression of SOX2,
OCT4, NANOG, BMI1, and CXCR4 was evalu ted by q T-PCR using β-ACTIN as endogenous control.
Bar graphs represent average ±1 SD of thr e ind pendent experiments (n = 3). Statist cal significance
was determined by on - y ANOVA with a post hoc Turkey test. (* p < 0.5, ** p < 0.01, ** p < 0.001,
**** p < 0.0001) by comparing CmpdA-treated groups with the DMSO-treated group.
Int. J. Mol. Sci. 2020, 21, 5806 5 of 19
2.3. IKKβ Targeting Reduces Tumoursphere Formation, Self-Renewal, and Preferentially Impairs Proliferation of
TIC-Enriched KRAS-Mutant Cells
After determining that IKKβ promotes the expression of stemness-related genes, we sought out to
investigate how IKKβwould affect TIC function. For that purpose, we treated A549 and H358 cells with
CmpdA and analysed tumoursphere formation and TIC proliferation. We found that CmpdA reduced
the ability of A549 and H358 cells to form tumourspheres in a dose-dependent manner (Figure 3A).
This reduction in tumoursphere formation is not caused by cell death, as CmpdA treatment did not
significantly increase A549 or H358 cell death (Figure S3A). Moreover, whereas CmpdA treatment did
not affect the ability of adherent A549 cells to form colonies, it decreased colony formation of A549
tumoursphere-derived TIC-enriched cells by half (Figure 3B). It is noteworthy that, even though CmpdA
did not affect the number of colonies formed by adherent A549 cells, it did affect colony size (Figure 3B).
This can be explained by the fact CmpdA leads to a dose-dependent reduction in A549 proliferation
(Figure S3B). In accordance, whereas CmpdA treatment of adherent A549 cells led to a dose-dependent
decrease in proliferation, resulting, after 72 h, in a 4% reduction at 5 µM CmpdA and a 16% reduction
at 10 µM CmpdA respectively (Figure 3C), CmpdA treatment of A549 tumoursphere-derived cells led
to a much more pronounced decrease in proliferation, resulting, after 72 h, in a 16% reduction at 5 µM
CmpdA and a 45% reduction at 10 µM CmpdA respectively (Figure 3C). These results indicate that
IKKβ targeting preferentially impairs proliferation of TIC-enriched KRAS-mutant cells.
In order to evaluate the impact of IKKβ targeting on TIC self-renewal, we targeted IKKβ in A549
and H358 cells by small interfering RNA (siRNA)-mediated transfection and evaluated the ability
of targeted cells to form tumourspheres in serial passages. As can be seen in Figure 4A, IKKβ or
KRAS targeting by siRNA-mediated transfection resulted in a 92% and 79% reduction in IKKβ protein
expression and a 64% and a 22% in reduction in RAS protein expression in A549 and H358 cells,
respectively (Figure 4A and Figure S4). This reduction in protein expression was associated with a 70%
and 63% reduction in IKKβ mRNA expression, and an 81% and a 71% in reduction in KRAS mRNA
expression in A549 and H358 cells, respectively (Figure 4B). The lower reduction of KRAS observed at
the protein level compared to the mRNA level stems from the fact that the antibody used to detect
KRAS also detects the NRAS and HRAS isoforms, which are not targeted by the siRNA used. Taken
together, these results indicate that our siRNA targeting approach was successful.
Interestingly, IKKβ targeting by RNA interference decreased the ability of A549 cells to form
primary tumourspheres by 80%, secondary tumourspheres by 60% and tertiary tumourspheres by
80%. These results were recapitulated by targeting KRAS, which also resulted in a similar reduction in
primary (80%), secondary (40%) and tertiary (70%) tumoursphere formation (Figure 4C). Even though
serial tumoursphere passage analysis was not feasible in H358 cells, due to the fact that an insufficient
number of cells were available for passage into secondary cultures when IKKβ or KRAS was targeted,
siRNA-mediated IKKβ or KRAS targeting also significantly reduced primary tumoursphere formation
(by approximately 60% for both IKKβ and KRAS, Figure 4D). Interestingly, whereas H358 cells have
been shown to be sensitive to KRAS inhibition, A549 cells do not lose viability upon KRAS inhibition
and both are resistant to IKKβ inhibition under adherent conditions [22]. Therefore, even though we
cannot rule out the possibility that the reduction in primary tumoursphere formation in H358 cells
upon KRAS silencing may reflect a loss of intrinsic viability, the reduction observed in A549 cells
and upon IKKβ inhibition cannot be attributed to an intrinsic cell viability loss. Therefore, taken
together, these results indicate that the KRAS/IKKβ pathway promotes lung tumoursphere formation
and self-renewal, thereby implicating that targeting this pathway may affect TIC function.
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Figure 3. IKKβ targeting with CmpdA reduces tu oursphere formation and preferentially impairs
proliferation of KRAS-mutant tumoursphere-derived cells. (A) A549 and H358 cells were treated
with the indicated concentrations of CmpdA or with vehicle control (0.1% DMSO) and plated for
tumoursphere cultures. Tumoursphere number was determined by manual counting. Images shown
are representative of three independent experiments (n = 3). White scale bars represent 50 µm.
(B) Clon genic assays of A549 adherent cells treated with CmpdA or vehicle c l (0.1% DMSO) were
compared to clonogenic assays of A549 cells derive from CmpdA-treated or control-treated (0.1%
DMSO) tumourspheres. Adherent or tumoursphere-derived cells were plated and colonies formed were
stained with crystal violet. Colony number and colony area were quantified using Image J software.
Images shown are representative of three independent experiments (n = 3). (C) Growth curves measured
by IncuCyte time-lapse video microscopy of adherent-derived and tumoursphere-derived A549 cells
upon treatment with 0.1% DMSO and 5 µM CmpdA (left) or 10 µM CmpdA (right). A representative
growth curve of two independent experiments (n = 2) is shown for each condition. Error bars show
±1 SD for technical triplicates. In all cases, bar graphs represent average ± 1 SD of three independent
experiments (n = 3). Statistical significance was determined by one-way ANOVA with a post hoc
Turkey test (* p < 0.5, *** p < 0.001) (A) or by Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001, ns = not
significant) (B), by comparing CmpdA-treated groups with the DMSO-treated group.
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Figure 4. Small interferi g RNA (siRNA)-medi I Kβ targeting reduces tumoursphere formation
and self-renewal of KRAS-mutant lung cancer cells. A549 and H358 cells were transfected with
a non-targeting control siRNA (siCtrl) or with siRNA SMARTpools targeting KRAS (siKRAS) or
IKKβ (siIKKβ) as described in methods. (A) Protein lysates were collected 96 h post-transfection
and evaluated by Western Blotting with the indicated antibodie . Protei bands w re quantitated
and normalized to the reference samples (siCtrl samples). Nitrocellulose membrane was cut before
probing with the respective primary antibody. Lanes from blots cropped from different membranes
are separated by a black line and full membrane blots are presented in Figure S4. Images shown are
representative of three independent experiments (n = 3). (B) Expression of KRAS (left panel) or IKKβ
(right panel) was analysed 72 h post-transfection by RT-qPCR in each cell line as indicated using GAPDH
as endogenous control. (C) Serial tumoursphere formation assay of siKRAS- or siIKKβ-transfected
A549 cells compared to siCtrl-transfected A549 cells. Representative images of primary, secondary
and tertiary A549 tumourspheres for each siRNA transfection condition are shown. White scale bar
represents 100 µm. (D) Primary tumoursphere formation assay of siKRAS- or siIKKβ-transfected
H358 cells compared to siCtrl-transfected H358 cells. Representative images of H358 tumourspheres
for each siRNA transfection condition are shown. White scale bar represents 100 µm. In all cases,
bar graphs represent average ±1 SD of three independent experiments (n = 3). Statistical significance
was determined by the Student’s t-test (**** p < 0.0001) by comparing siCtrl-transfected groups with
siKRAS- or with siIKKβ-transfected groups (B) or by one-way ANOVA with a post hoc Turkey test
(* p < 0.5, ** p < 0.01, *** p < 0.001) (C and D). Groups being compared are indicated by horizontal bars.
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2.4. IKKβ Kinase Targeting Reduces KRAS-Mutant Lung Cell Migration and Invasion
In addition to the ability to self-renew, TICs are thought to be responsible for metastatic
dissemination and TICs have been shown to be intrinsically migratory and invasive [28]. Because IKKβ
promotes TIC function and because it activates the NF-κB pathway, which has also been implicated in
promoting metastasis in different tumour models [29], we hypothesized that it would also promote
KRAS-induced migration and invasion. Intriguingly, we found that IKKβ targeting by CmpdA in A549
and H358 cells reduces expression of matrix metalloproteinases 2 (MMP2) and 9 (MMP9) (Figure 5A),
which are involved in promoting cell invasion [30]. Based on this result, we evaluated the effect of
IKKβ targeting with CmpdA on cell migration and invasion. Although H358 cells did not migrate
in transwell and wound-healing assays, even in control conditions, CmpdA treatment significantly
reduced A549 cell transwell migration independent of CmpdA dose, as an 85% reduction was observed
with 5 and 10 µM of CmpdA (Figure 5B). In accordance with this result, CmpdA treatment also reduced
A549 wound-healing migration (Figure 5C). This reduction was more pronounced 48 h after CmpdA
administration, where a 16% reduction was observed with 5 µM CmpdA and a 30% reduction with
10 µM CmpdA (Figure 5C). Moreover, IKKβ targeting with CmpdA reduced A549 invasion (Figure 5D)
in a dose-independent manner, as a reduction of 82% and 83% were observed with 5 and 10 µM
CmpdA, respectively. Interestingly, even though H358 cells did not display a migratory phenotype,
they were invasive, which suggests that signalling by matrix proteins present in Matrigel is crucial to
activate H358 migration. Similarly to what we observed with A549 cells, IKKβ targeting with CmpdA
in H358 cells also reduced cell invasion, but in a dose-dependent manner, as a 70% and 90% reduction
was observed with 5 µM and 10 µM CmpdA, respectively (Figure 5E).
These results were further corroborated by IKKβ targeting by RNA interference. siRNA-mediated
IKKβ inhibition in both A549 and H358 cells reduced expression of MMP2 by 60% and 70% and
MMP9 by 75% and 55%, respectively (Figure 6A). siRNA-mediated KRAS targeting led to similar
reductions in MMP2 expression in both cell lines (Figure 6A). Moreover, even though KRAS targeting
did not affect MMP9 expression in A549 cells, it reduced MMP9 expression by 55% in H358 cells
(Figure 6A). Next, we assessed if this reduced expression would be associated with reduced MMP
activity. We found that MMP2 activity is similarly reduced by IKKβ or KRAS targeting in both A549
and H358 cells (Figure 6B), whereas IKKβ or KRAS targeting did not affect MMP9 activity (Figure 6B).
Even though some differences in MMP expression and activity upon IKKβ targeting were observed
between cells lines, all cell lines displayed reduced expression and/or activity of at least one MMP,
corroborating the results we obtained with CmpdA treatment.
We next evaluated how siRNA-mediated IKKβ targeting would affect cell migration and invasion.
IKKβ targeting reduced A549 cell migration and invasion by 38% and 50%, respectively (Figure 6C,D).
This result was phenocopied by siRNA-mediated KRAS targeting, which reduced A549 migration
and invasion by 46% and 41%, respectively (Figure 6C,D). Even though H358 cells do not display a
migratory phenotype, both siRNA-mediated IKKβ and KRAS targeting reduced the invasive phenotype
of these cells by 66% and 69%, respectively (Figure 6E). Similar to what we observed for tumoursphere
formation, even though we cannot rule out the possibility that the reduction in H358 cell invasion upon
KRAS silencing may reflect a loss of intrinsic viability caused by KRAS suppression, the reduction in
migration and invasion observed in A549 cells and upon IKKβ inhibition cannot be attributed to an
intrinsic cell viability loss. Taken together, these results demonstrate that IKKβ promotes KRAS-mutant
lung cell migration and invasion potentially by promoting expression and activity of MMP2.
In conclusion, our results show that IKKβ promotes KRAS-induced stem-like and malignant traits,
which indicates that IKKβ is likely involved in promoting tumour recurrence and aggressiveness,
thereby suggesting IKKβ inhibition as a relevant therapeutic approach for KRAS-induced lung cancer.
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Figure 5. IKKβ kinase targeting with Compound A reduces the expression of matrix metalloproteinase
genes, tumour cell migration and invasion. A549 and H358 cells were treated with 0.1% DMSO or the
indicated concentrations of CmpdA. (A) After 24 h, expression of MMP2 and MMP9 was evaluated
by RT-qPCR using β-ACTIN as endogenous control. (B) After 24 h, transwell migrati n assays were
performed as described in methods. Images hown are pre entative of three indepen ent experiments
(n = 3). White scale bar represents 100 µm. (C) Real-time wound healing assays of A549 cells were
performed by IncuCyte time-lapse video microscopy over 72 h of treatment with 0.1% DMSO or the
indicated concentrations of CmpdA. Results are expressed as percentage of confluence in the wound.
A representative wound confluence curve of two independent experiments is shown for each condition.
Error bars show ±1 SD for technical triplicates. Representative images of A549 wound-healing assays
at 0, 24 and 48 h are shown. White scale bar represents 300 µm. (D) After 24 h of treatment of A549
and (E) H358 cells with 0.1% DMSO or the indicated concentrations of CmpdA, transwell invasion
assays were performed as described in methods. Images shown are representative of three independent
experiments (n = 3). White scale bars represent 100 µm. In all cases, bar graphs represent average
±1 SD of three independent experiments (n = 3). Statistical significance was determined by one-way
ANOVA with a post hoc Turkey test. (* p < 0.5, ** p < 0.01, *** p < 0.001, ns = not significant). Groups
being compared are indicated by horizontal bars.
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Figure 6. siRNA-mediated targeting of IKKβ or KRAS reduces the expression and activity of matrix
metalloproteinases, tumour cell migration and invasion. A549 and H358 cells were transfected
with a non-targeting control siRNA siCtrl) or with siRNA S ARTpools targeting KRAS (siKRAS)
or IKKβ (siIKKβ) as described in methods. (A) After 72 h, expression of MMP2 and MMP9 was
evaluated by RT-qPCR using GAPDH as endogenous control. (B) Conditioned culture medium was
collected 96 h post-transfection and matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9
(MMP9) activity was determined using ELISA-based Biotrack Activity Assay Systems (GE Healthcare).
(C) Transwell cell migration assays were performed as described in methods 96 h post-transfection.
Images shown are representative of three independ nt experiments (n = 3). Whit scal bar represents
50 µm. (D) Tra swell cell invasion s ays for A549 and (E) H358 were performed as described in
methods 72 h post-transfection. Images shown are representative of three independent experiments
(n = 3). White scale bars represent 50 µm. In all cases, bar graphs represent average ±1 SD of three
independent experiments (n = 3). Statistical significance was determined by one-way ANOVA with a
post hoc Turkey test (* p < 0.05, *** p < 0.001, **** p < 0.0001). Groups being compared are indicated by
horizontal bars.
3. Discussion
Tumour-initiating cells (TICs) represent a subpopulation of highly tumourigenic cancer cells with
stem-like prop rties that are directly involved with therapy resistance, metastas s and recurrence [6].
The identification and targeting of these cells remain challenging due to their plastic behaviour, as well
as the lack of knowledge on the molecular mechanisms that distinguish them from the other cells of the
tumour bulk. Here, we present evidence that KRAS-driven TICs have increased IKKβ kinase activity,
which, not only promotes stemness, but is also involved in tumour cell migration and invasion.
These findings are novel and relevant in various ways. First, accumulating evidence demonstrates
that KRAS, one of the most frequently mutated genes in human cancers, plays a critical role in the
Int. J. Mol. Sci. 2020, 21, 5806 11 of 19
maintenance of a cancer stem-like phenotype. KRAS is not only able to impair the differentiation of
endodermal progenitors in vitro when exposed to retinoic acid [31], but also promotes maintenance
and expansion of TICs in breast cancer [12,32], keratinocytes [33], prostate cancer [16], colon cancer [34],
pancreatic cancer [14] and lung cancer [15].
Second, since the acquisition of stemness behaviour and malignant traits are linked through the
epithelial-mesenchymal transition (EMT) program [35], it is not surprising that, in addition to promoting
stemness, KRAS has also been implicated in promoting EMT, invasion and metastasis [9,11,36]. In fact,
KRAS not only promotes EMT [10] and autophagy-dependent invasion [36], but also drives colorectal
metastasis formation [11].
Finally, in spite of this evidence, the pathways triggered by KRAS to promote stemness, invasion
and metastasis are only now beginning to emerge [14,15,34], most of which can be related to the
IKK/NF-κB pathway. For example, KRAS has been shown to activate NF-κB in a ras-like proto-oncogene
B (RalB)-dependent manner in order to promote stemness and drug resistance [13]. Additionally, IKKβ
is a downstream target of protein kinase C iota (PKCι) [37], and PKCι targeting in KRAS-driven TICs
greatly impairs tumourigenic potential in immunocompromised mice, tumoursphere formation and
the expression of stemness-related genes [15]. Moreover, KRAS binds calmodulin and interfering with
calmodulin binding reduces phosphatidylinositol 3-kinase PI3K activity and PI3K-mediated EMT,
invasion and metastasis [38]. Interestingly, PI3K can activate the IKK/NF-κB pathway [39]. In accordance
with the pathways uncovered by these reports, we show that KRAS-mediated maintenance of lung
TIC activity and cell migration and invasion depends on IKKβ and, thereby, we identify IKKβ as a
new druggable KRAS target involved in promoting a stem-like and invasive phenotype.
Consistent with its role as a canonical activator of NF-κB [19], which is activated in TICs from
various cancers [20], and also promotes EMT and induces TIC activity in lung cancer [40], recent
studies have shown that IKKβ can also promote cancer stemness. IKKβ targeting reduces breast
cancer mammosphere formation and tumourigenicity [41], and positively regulates Lin28B and
SRY (sex determining region Y)-box 2 (SOX2) to promote breast cancer stemness [42] and reduces
breast GD2+ TICs, thereby reducing metastasis [43]. Consistently, an IKKβ inhibitor was identified
as a hit in a screening of breast TIC inhibitors [44]. In addition, IKKβ targeting reduces prostate
cancer tumoursphere formation and expression of stem cell factors [45], as well as reduces the ability
of CD133+ glioblastoma TICs to form tumourspheres [46]. Moreover, IKKβ upregulates the long
noncoding RNA HOX transcript antisense RNA (HOTAIR) to promote liver cancer stem cell growth
in vitro and in vivo [47]. Finally, another study found that BMS-345541, an allosteric site-binding
inhibitor of IKKβ, decreases tumoursphere formation and the expression of stem cell transcription
factors of CD166+/CD44+ and CD166+/epithelial cell adhesion molecule (Epcam)+ A549 cells [48].
Here, we show, not only that IKKβ activity is increased in KRAS-mutant lung tumourspheres (Figure 1),
but also that IKKβ targeting in KRAS-mutant lung cancer cells reduces expression of stem cell factors
(Figure 2), as well as KRAS-mutant lung tumoursphere formation and self-renewal (Figures 3 and 4).
We also show that A549 tumoursphere-derived cells are preferentially sensitive to CmpdA (Figure 3),
suggesting IKKβ inhibition as an interesting approach to selectively target KRAS-mutant TICs.
In addition to its role in promoting KRAS-induced stemness, we found that IKKβ also promotes
KRAS-induced migration and invasion (Figures 5 and 6). This is supported, not only by the
well-established role of the NF-κB pathway in promoting invasion and metastasis [49], but also
by studies showing that IKKβ is involved in promoting malignant behaviour. For example, in breast
cancer, IKKβ-dependent NF-κB activation is essential to drive EMT and metastatic dissemination [50].
Furthermore, IKKβ targeting reduces EMT and metastasis in a colorectal mouse model of tumour
progression [51] and reduces oral squamous carcinoma and prostate cancer cell invasion [52]. Finally,
angiogenesis contributes to metastatic dissemination by shared mediators, such as the interleukin
8 (IL-8) cytokine [25,53], and IKKβ has been shown to upregulate IL-8 to promote lung cancer
angiogenesis and ovarian cancer angiogenesis and metastasis [24,54].
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Because invasion and metastasis are frequently associated with altered expression and activity
of matrix metalloproteinases 2 (MMP2) and 9 (MMP9) [55], and because both have been shown to
be regulated by NF-κB [19], we investigated how IKKβ and KRAS targeting affected the expression
and activity of MMP2 and MMP9 (Figure 6). Even though IKKβ targeting reduced the expression of
MMP9 as expected, surprisingly KRAS targeting only significantly decreased the expression of MMP9
in H358 cells. This cell type-specific regulation of MMP9 expression by KRAS could stem from the fact
that, whereas A549 cells are homozygous for KRASG12S, H358 cells are heterozygous for KRASG12C.
Not only different KRAS mutant forms have been shown to result in preferential activation of different
signalling pathways, but wild type KRAS has been shown to have an inhibitory effect on the oncogenic
KRAS form in cells that are heterozygous for KRAS mutations [56]. Nonetheless, MMP9 expression
regulation by the KRAS/IKKβ pathway in these cells is likely unimportant, as targeting either KRAS
or IKKβ in both lung cancer cell lines did not affect MMP9 enzymatic activity. On the other hand,
IKKβ or KRAS targeting reduced both the expression and activity of MMP2, thus suggesting that
KRAS-induced invasion is mediated, at least in part, by IKKβ-induced MMP2 expression. In support
of this idea, KRAS has been shown to promote MMP2 expression and activity [57].
Interestingly, a recently published report claims that IKKα, the other catalytic subunit of the IKK
complex, would be a better actionable target in KRAS-induced lung cancer, suggesting combined IKKα
and IKKβ inhibition as a therapeutic approach [58]. It is possible that IKKβ targeting would affect IKKα
activity, at least in part, as both associate in the IKK complex, but IKKα homodimers also associate in a
second IKK complex that acts independently of IKKβ [19]. Nonetheless, IKKα’s role in KRAS-induced
lung cancer remains controversial, as a second report claims that IKKα acts as a tumour suppressor
and that IKKα genetic deletion actually promotes KRAS-induced lung cancer [59]. It is interesting and
reassuring that these recently published antagonistic reports do not rule out IKKβ as a relevant target
in KRAS-induced lung cancer. Our data gives support to the relevance of IKKβ as a therapeutic target
by providing insight about the mechanism whereby IKKβ promotes KRAS-induced tumorigenesis.
Taken together, our results identify IKKβ as an important mediator of KRAS-induced stemness
and invasion in lung cancer and indicate that IKKβ inhibition might selectively target cells with
stem cell and invasive traits. This is important, not only because it further underscores the relevance
of IKKβ as a therapeutic target for KRAS-induced lung cancer, but also because it suggests that
using IKKβ inhibition therapy as an adjuvant approach to standard chemotherapy might constitute a
promising strategy to lower recurrence rates, reduce metastatic dissemination and improve survival of
KRAS-induced lung cancer patients.
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
Human lung cancer cell lines harbouring KRAS mutations A549 (KRASG12S) and H358 (KRASG12C)
were obtained from the American Type Culture Collection (ATCC; Manassas, VA,USA) and
authenticated by short tandem repeat profiling at ATCC. Cells were grown in RPMI 1640 (Thermo
Fisher Scientific, Waltham, MA, USA) with 10% foetal bovine serum (FBS, Sigma-Aldrich, St. Louis,
MO, USA) in a humidified incubator at 37 ◦C and 5% CO2. Cells were treated with IKKβ inhibitor
Compound A (CmpdA) [27] (kindly provided by Albert Baldwin) or 0.1% dimethyl sulfoxide (DMSO,
vehicle control) as indicated in the figure legends.
4.2. Tumoursphere Formation
To generate TIC-enriched tumourspheres, 1 × 103 cells (for counting and replating experiments)
or 5 × 103 cells (for protein and RNA analysis) were seeded in 6-well ultra-low attachment plates
(Corning Inc., New York, NY, USA) and cultured in serum-free medium DMEM/F12 (Gibco, Carlsbad,
CA, USA) supplemented with 20 ng/mL FGF (PeproTech, Rocky Hill, NJ, USA), 20 ng/mL EGF
(PeproTech) and 1X N2 supplement (Gibco) for 14 days. Every 3 days, each well was supplemented
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with 500 µL of the same medium. After 14 days, tumoursphere number was determined by manual
counting. Alternatively, tumourspheres were collected for protein or RNA analysis or for replating
experiments. For replating assays, tumourspheres were dissociated with StemPro® Accutase (Thermo
Fisher Scientific) and reseeded for secondary and tertiary tumoursphere cultures (1 × 103 cells) or for
clonogenic assays (as described below). Treatment with Compound A was performed as described in
the figures only once during seeding and siRNA transfection was performed 72 h before seeding of
primary tumoursphere cultures.
4.3. siRNA Transfections
A549 and H358 cells were seeded in 6-well-plates (1 × 105 cells/well) 12 h before transfection.
siRNA transfections were performed using 50 nM of either siRNA SMARTpools targeting KRAS
or IKKβ or a non-targeting siRNA control (Dharmacon, Lafayette, CO, USA) according to the
manufacturer’s instructions.
4.4. Clonogenic Assay
Adherent and tumoursphere-derived cells were seeded at 5 × 102 cells (A549) or 5 × 103 cells
(H358) per plate in 60 mm or 6-well adherent plates in triplicate. Cells were allowed to form colonies
for 2 weeks with medium changed twice a week. Colonies were stained with 0.5% crystal violet
solution for 10 min and colony number and/or area was quantified using ImageJ software (version
1.51, National Institutes of Health, Bethesda, MD, USA).
4.5. Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) following the
manufacturer’s protocol and cDNA synthesis was performed with 1 µg of total RNA using Superscript
III reverse transcriptase (Thermo Fisher Scientific). Relative expression of BMI1, CD24, CXCR4, SOX2,
OCT4, NANOG, KRAS, IKKβ, MMP2, and MMP9 was analysed by real-time PCR performed in a
StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR® Green
Master Mix (Thermo Fisher Scientific). Relative quantitation was performed by the ∆∆Ct method using
β-ACTIN or GAPDH as endogenous controls. Primer sequences for each gene are described in Table S1.
4.6. Western Blotting
Radioimmunoprecipitation Assay (RIPA)Hi buffer (150 mM NaCl, 50 mM Tris–HCl pH 7.5, 1%
NP-40, 0.5% sodium deoxycholic acid, 1% SDS) containing protease and phosphatase inhibitors
(Complete protease/phosphatase inhibitor cocktails, Sigma-Aldrich) was used to prepare whole cell
lysates. Protein concentration was determined using Bradford Reagent (BioRad, Hercules, CA, USA)
and electrophoresis was conducted with 50 µg of protein per lane in 12% polyacrylamide minigels in
running buffer (25 mM Tris, 190 mM glycine, and 0.1% SDS) at 120 V for 60–90 min, followed by transfer
to nitrocellulose membranes (Merck Millipore, Burlington, MA, USA) with Towbin buffer (25 mM Tris,
192 mM glycine, 20% methanol) at 250 V for 2.5 h. Membranes were blocked with 5% milk solution
in TBST (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween- 20) for 1 h at room temperature. Finally,
membranes were incubated with primary antibodies diluted in TBST containing 5% BSA and 0.1% NaN3
for 16 h at 4 ◦C, washed 3 times in TBST and incubated with Horseradish Peroxidase (HRP)-conjugated
secondary antibodies diluted in TBST for 1 h at room temperature. Chemiluminescence detection was
performed using Pierce Enhanced Chemiluminescent (ECL) Western Blotting Substrate (Thermo Fisher
Scientific) in a ChemiDoc MP Imaging System (BioRad). The following primary ant following primary
ant ibodies were used: anti-phospho-IκBαSer32 (1:1000, Cell Signalling, Danvers, MA, USA), anti-IκBα
(1:1000, Cell Signalling), anti-β-Actin (1:7000, Sigma-Aldrich), anti-IKKβ (1:1000, Cell Signalling,
Danvers, MA, USA), anti-PanRAS (1:1000, Merck Millipore), and anti-α-tubulin(1:2000, Sigma-Aldrich).
The following secondary antibodies were used: HRP anti-rabbit (1:7000, GE Healthcare, Chicago, IL,
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USA) and HRP anti-mouse (1:7000, GE Healthcare). Protein bands of interest were quantitated using
ImageJ as indicated in the figure legends.
4.7. Cell Proliferation, Cell Death and Wound-Healing Assays
Cell proliferation, cell death and wound-healing assays were analysed by IncuCyte time-lapse
video microscopy (Essen Bioscience, Hertfordshire, UK). For cell proliferation and cell death, 3× 103 cells
(A549) or 9 × 103 cells (H358) were plated in a 96-well clear-bottomed black tissue culture plate (BD
Falcon). On the next day, cells were treated with CmpdA or vehicle control (0.1% DMSO) as indicated
in the figure legends. Cell proliferation was monitored over 96 h by recording cell density every
3 h. Cell death measurements were performed after 72 h of drug treatment using the IncuCyte®
Sytox Green Reagent (1/1000) to label dead cells. To calculate the percentage of dead cells, total cell
number was quantified by incubation with 0.5% Triton X-100 for 1 h to permeabilise all cells to the
Sytox dye. For wound-healing assays, 2.5 × 104 A549 cells were plated in an ImageLock 96-well plate
(Essen Bioscience). Cells were grown to confluence and a wound was created using the WoundMaker
apparatus (Essen Bioscience) according to manufacturer instructions. The wells were then washed
twice with PBS and medium was replaced according to the experiment design (0.1% DMSO or
increasing doses of CmpdA). Plates were imaged over 96 h and cell density in the wound was recorded
every 2 h. Data were analysed using the IncuCyte Confluence version 1.5 software, which quantified
cell surface area coverage as confluence values. IncuCyte experiments were performed in triplicate.
Two independent experiments were performed with technical triplicates and a single representative
growth curve is shown for each condition.
4.8. Transwell Migration Assays
Migration assays were performed as previously described [24]. Briefly, using 24-well transwell
inserts with 8 µm pore membrane filters (Corning). For pharmacological studies, migration assays
were performed 24 h after A549 cells were treated with the IKKβ inhibitor CmpdA. Alternatively, cells
were transfected with siRNAs as described above and migration was analysed 72 h post-transfection.
In both cases, for each well 5 × 104 A549 cells were resuspended in 300 µL serum-free medium, added
to the upper chamber and incubated for 24 h at 37 ◦C in 5% CO2. Complete medium (500 µL) was
added to the lower chamber to be used as chemoattractant. Non-migrating cells were scraped off the
upper surface of the membrane with a cotton swab, and migrating cells on the bottom surface were
fixed in 4% paraformaldehyde in PBS and stained with crystal violet. Images were obtained under an
IX51 Inverted Microscope (Olympus, Tokyo, Japan) and cells from three random fields of view from
three independent experiments were analysed using ImageJ software.
4.9. Invasion Assay
Invasion assays were performed using Matrigel-coated 24-well transwell inserts with 8 µm pore
membrane filter (Corning Inc.). For pharmacological studies, invasion assays were performed 24 h
after A549 cells and H358 cells were treated with the IKKβ inhibitor CmpdA. Alternatively, A549 cells
and H358 cells were transfected with siRNAs and invasion was analysed 72 h post-transfection. In both
cases, A549 (3 × 104 cells per well) or H358 cells (6 × 104 cells per well) were resuspended in 300 µL
serum-free medium, added to the upper chamber and incubated for 24 h (A549 cells) or 48 h (H358
cells) at 37 ◦C in 5% CO2. Complete medium (500 µL) was added to the lower chamber to be used as
chemoattractant. Non-invading cells were scraped off the upper surface of the membrane with a cotton
swab, and invading cells on the bottom surface were fixed in 4% paraformaldehyde in PBS and stained
with crystal violet. Images were obtained under an IX51 Inverted Microscope (Olympus). Cells from
three random fields of view from three independent experiments were counted using ImageJ software.
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4.10. Measurement of MMP2 and MMP9 Activity
A549 cells and H358 cells were transfected with a non-targeting control siRNA (siRNA) or
with siRNA SMARTpool, targeting KRAS (siKRAS) or IKKβ (siIKKβ) and conditioned medium was
collected 96 h post-transfection. Then, MMP2 and MMP9 activity levels were measured using specific
Biotrak assay systems (MMP2 Biotrack Activity Assay RPN 2631 and MMP9 Biotrak Activity Assay
RPN 2643, GE Healthcare) according to the manufacturer’s instructions. Each cell line was analysed
in triplicate.
4.11. Statistical Analysis
Statistical analysis was performed using Prism 8 (GraphPad Software) as previously described [24].
All values are presented either as average ± SD or as representative images of at least two independent
experiments. All data have been evaluated for normality of distribution. In order to assess significance
in multiple comparisons, one-way analysis of variance (ANOVA) was used with a post hoc Turkey test.
For pairwise comparisons, we used a non-parametric Student’s t test. Differences were considered
statistically significant at p < 0.05.
4.12. Data Availability
The datasets generated during and/or analysed during the current study are available from the
corresponding author on reasonable request.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/16/
5806/s1.
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Abbreviations
BMI1 B cell-specific Moloney murine leukaemia virus integration site 1
CmpdA Compound A
CD24 Cluster of differentiation 24
CXCR-4 C-X-C chemokine receptor type 4
DMSO Dimethyl sulfoxide
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
IKKβ Inhibitor of nuclear factor kappa-B kinase β
IκB Inhibitor of nuclear factor kappa-B
MMP2 Matrix metalloproteinase 2
MMP9 Matrix metalloproteinase 9
NF-κB Nuclear factor-kappa-light-chain-enhancer of activated B cells
OCT4 Octamer-binding transcription factor 4
SOX2 SRY (sex determining region Y)-box 2
siRNA Small interfering RNA
TICs Tumour-initiating cells
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